Ruscica, Francesca (2021) Nabiximols in Multiple Sclerosis-Related Spasticity. European Journal of Case Reports in Internal Medicine, 8 (Sup 2). pp. 13-15. ISSN 2284-2594
|
Text
Nabiximols in Multiple Sclerosis-Related Spasticity.pdf - Published Version Download (2MB) | Preview |
Abstract
Multiple sclerosis (MS) is a chronic, autoimmune disease caused by inflammation and neurodegeneration, which is associated with a wide spectrum of central nervous system symptoms. Spasticity, defined as abnormally increased muscular tone, is 1 of the most common disabling symptoms in MS, occurring in up to 80% of MS patients and showing increased severity as the disease progresses over time. The approval of nabiximols for the management of MS spasticity opened up a new treatment opportunity to many patients. Here, we report a case of a 43-year-old man with a primary progressive MS diagnosis and spasticity-associated symptoms. Nabiximols had significant benefits with respect to spasticity symptoms.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Multiple sclerosis, spasticity, Sativex® |
| Subjects: | 600 Tecnologia - Scienze applicate 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 01 Feb 2022 10:06 |
| Last Modified: | 01 Feb 2022 10:06 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21472 |
Actions (login required)
 |
View Item |
